Wellcome Leap Q4Bio program maps credible path to quantum advantage in health
A US nonprofit’s $50 million challenge produced the first genome encoded on quantum hardware
Philanthropy, not government funding or venture capital, bankrolled one of the most rigorous attempts to date to determine whether quantum computing can deliver practical value in human health. After 30 months and $50 million, the results are in.
Wellcome Leap, a US nonprofit founded by the Wellcome Trust, designed its Quantum for Bio (Q4Bio) program around a question the rest of the funding landscape was unwilling to ask: could quantum algorithms deliver a provable advantage for biological problems that classical computers cannot solve?
The program has produced a prize winner, a world first in genomics and a set of computational frameworks that did not exist when it began.
“Q4Bio was designed to create new solutions that would answer that question within real biological and hardware constraints. What we now have is a much clearer understanding of where quantum can create value, where it cannot, and what needs to happen next,” said Shihan Sajeed, program director for Q4Bio at Wellcome Leap.
“When we started the Wellcome Leap program, it wasn’t clear exactly how or where quantum computing could meaningfully impact biology,” he said.
The program rested on a structural insight. The intersection of quantum computing and biology presented a class of problems that governments considered too uncertain to fund, and that venture capital found too distant in its payoff horizon to back. Problems of that kind are routinely left unaddressed. Sajeed said that the gap was precisely where Wellcome Leap was built to intervene.
To anchor the stakes, Sajeed opened his presentation with six clinical scenarios, among them a child with a rare form of myotonic dystrophy, a young woman with skin cancer, a single mother whose cancer was growing at an alarming rate and an elderly woman uncertain whether her body could tolerate her prescribed therapy.
Each scenario pointed to a quantum-enhanced solution that does not yet exist.
He asked whether the field should wait for the incremental pace of science or take deliberate steps to accelerate. Q4Bio was Wellcome Leap’s answer.
Wellcome Leap is a US nonprofit founded by the Wellcome Trust in 2020 with a mandate to run unconventional, large-scale programs and deliver breakthroughs in human health in years rather than decades. Q4Bio was its only quantum-focused program.
Genome on quantum hardware
Sajeed delivered the talk, titled “Foundations as Kingmakers: How Philanthropy is Shaping the Quantum Era,” at Commercialising Quantum Global 2026, an Economist Enterprise event held in London on June 16.
The session examined how philanthropic funders are shaping early-stage quantum research and what Q4Bio’s results reveal about where quantum computing can and cannot yet create value in healthcare.
Q4Bio launched in September 2023 with $40 million in research funding distributed across three phases and up to $10 million in prize money.
Two prize tiers were defined:
a $5 million grand prize for teams demonstrating full quantum advantage over best-in-class classical baselines;
a $2 million prize for each team that demonstrated an experimental realization on a quantum computer with more than 50 qubits and a clear trajectory toward advantage.
From 120 applicants, 12 teams were selected. Each received $1.5 million to identify biological problems amenable to quantum computing and develop candidate algorithms. Eight teams advanced to test those algorithms through high-performance computing (HPC) simulation, with funding of up to $750,000 each.
Six finalists then entered a 12-month hardware implementation phase, each receiving $2 million. The program formally concluded in March 2026.
The six finalist teams were led by Infleqtion, the University of Nottingham, Harvard University, Stanford University, Algorithmiq and the University of Oxford.
The team formed by Oxford, the University of Cambridge and the Wellcome Sanger Institute focused on genomics, building an end-to-end framework for mapping genome-scale problems onto quantum hardware.
Their headline result was loading the complete genome sequence of hepatitis D into a 117-qubit IBM quantum computer, the first time a complete organism’s genome had been encoded on quantum hardware. Current systems can only accommodate small molecules; as hardware scales, larger and more complex genomes become encodable.
“Wellcome Sanger Institute (previously known as The Sanger Center and Wellcome Trust Sanger Institute) was the institute where the first classical genome sequencing was done by Fred Sanger, which earned him the Nobel Prize in chemistry in the 80s,” Sajeed said. “Fifty years later, the same institute undertook the same problem, only this time in quantum.”
The tools and heuristics the team developed allow researchers to examine the HLA (human leukocyte antigen) region of human DNA, which governs immune responses and cancer cell evolution and has, until now, been among the most computationally intractable sections of the genome. Sajeed said the work opens pathways for personalized medicine, disease susceptibility analysis and cancer evolution research.
Quantum inside the pipeline
The sole prize winner of Q4Bio was announced in April 2026. The team led by quantum software company Algorithmiq, with quantum computing support from IBM and biological expertise from the Cleveland Clinic, was awarded $2 million after successfully meeting the scalability criteria. No team claimed the $5 million grand prize.
The team developed an end-to-end quantum-classical workflow to calculate the excited-state properties of TLD-1433, a photosensitizer molecule in phase two clinical trials for photodynamic cancer therapy. Using quantum-generated data, they boosted the performance of a classical DMRG (density matrix renormalization group) pipeline, marking the first time a quantum computer was integrated into a classical pipeline to improve overall output.
“We know in the near term it is more likely than not that quantum is not going to replace classical. It is actually going to coexist with classical, and we needed to know how it can happen,” Sajeed said.
The prize was awarded on the basis that the solution was scalable: its performance is expected to improve as quantum hardware advances. Sajeed described it as one of the first concrete demonstrations of a quantum computer lifting the performance of an entire classical pipeline.
Q4Bio also generated outcomes its designers had not anticipated. The constraints of running algorithms on noisy, low-resource quantum hardware forced teams to rethink and improve their classical pipelines as a side effect.
“The challenge of running a problem with those low-resource quantum hardware forced the teams to map the problem in a way so you can run it in those noisy quantum computers, and it needed them to improve the classical part of the computation, make it more efficient,” Sajeed said.
Teams discovered they had to improve every component of their computational frameworks simultaneously, because the underlying biological problem could only translate into value when all parts worked coherently. The resulting frameworks did not exist before the program launched. Sajeed said he expected them to grow stronger as hardware improves.
The experience reinforced Wellcome Leap’s core thesis: that bold, time-limited programs with competitive structures can pull forward research that would otherwise sit undone at the margins of mainstream funding.
Wellcome Leap is now designing a follow-on program and is actively seeking co-sponsors and partners.
Sajeed said the organization was still evaluating which problems it is best positioned to tackle next and had not yet settled on a name for the successor initiative. He said the pipelines and workflows built through Q4Bio are designed to adapt as more advanced quantum systems emerge.